{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-132925","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2024-12-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.746618+00:00","generated_at":"2026-05-28T21:28:16.189919+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Traws Pharma raises up to $72.6M; initial $20M tranche to fund Bird Flu drug","bullets":["Initial $20M gross proceeds from common stock and pre-funded warrants; net proceeds ~$17.9M.","Up to $52.6M additional from Series A Warrants exercisable after key Bird Flu data readouts (Ferret, NHP, Phase 2a).","Institutional investors: Perceptive Advisors, OrbiMed, Alyeska, Torrey Pines, Ikarian Capital.","Proceeds to accelerate Tivoxavir Marboxil development; cash runway extended into 1H26 (initial) and 3+ years if warrants exercised.","Closing on Dec 31, 2024; Series A Warrants subject to stockholder approval and 9.99% ownership limitation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-132925","json":"https://secwatch.observer/filing/0001104659-24-132925.json","markdown":"https://secwatch.observer/filing/0001104659-24-132925.md","text":"https://secwatch.observer/filing/0001104659-24-132925.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924132925/0001104659-24-132925-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465924132925/tm2432248d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T21:28:16.189919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}